Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Furneri, G ^a   Mantovani, L G ^b   Belisari, A ^a   Mosca, M ^c   Cristiani, M ^a   Bellelli, S ^d   Cortesi, P A ^a,e   Turchetti, G ^d  

^a Fondazione Charta   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d SCUOLA SUPERIORE SANT ANNA   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cost; Economic; Pharmacoeconomic; Review; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; ARTHROTEC; BIOLOGICAL FACTOR; CELECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLIXIMAB; METHOTREXATE; MISOPROSTOL; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RITUXIMAB; STEROID;

AGE; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE SEVERITY; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; JOINT INJURY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SHORT FORM 36; SOCIOECONOMICS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 84870288967     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (169)

1. GABRIEL SE: The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
2. LUNDKVIST J, KASTANG F, KOBELT G: The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8(Suppl. 2):S49-60.
3. GABRIEL SE: Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121(Suppl. 1):S9-14.
4. MAETZEL A, LI LC, PENCHARZ J et al.: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
5. JANTTI J, AHO K, KAARELA K, KAUTIAINEN H: Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology (Oxford) 1999;38:1138-41.
6. COYTE P, ASCHE C, CROXFORD R, CHAN B: The economic costs of arthritis and rheumatism in Canada. In: BADLEY EM, WILLIAMS JI, editors. Patterns of health care in Ontario: arthritis and related conditions. Toronto: Institute for Clinical Evaluative Sciences; 1998. p. 27-34.
7. BACKMAN CL: Employment and work disability in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:148-52.
8. SOKKA T, KAUTIAINEN H, MÖTTÖNEN T, HANNONEN P: Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999;26:1681-5.
9. ALLAIRE S, WOLFE F, NIU J, LAVALLEY M, MICHAUD K: Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005;53:603-8.
10. MICHAUD K, MESSER J, CHOI HK, WOLFE F: Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7, 527 patients. Arthritis Rheum 2003;48:2750-62.
11. GUYATT GH, OXMAN AD, KUNZ R et al.: Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-3.
12. LEE TJ, PARK BH, SON HK et al: Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea. Value Health 2012;15(1 Suppl.):S43-9.
13. SIMONS WR, ROSENBLATT LC, TRIVEDI DN: The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data. J Occup Environ Med 2012;54:48-55.
14. SCOTT DL: Biologies-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012;91:30-43.
15. JACOBS P, BISSONNETTE R, GUENTHER LC: Socioeconomic burden of immune-mediated inflammatory diseases-focusing on work productivity and disability. J Rheumatol Suppl 2011;88:55-61.
16. FERRACCIOLI G, GREMESE E: Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). Intern Emerg Med 2011;6(Suppl 1):11-5.
17. KIELY PD, DEIGHTON C, DIXEY J, OSTOR AJ; BRITISH SOCIETY FOR RHEUMATOLOGY STANDARDS, GUIDELINES AND AUDIT WORKING GROUP: Biologic agents for rheumatoid arthritis - negotiating the NICE technology appraisals. Rheumatology (Oxford) 2012;51:24-31.
18. LANGLEY PC, MU R, WU M, DONG P, TANG B: The impact of rheumatoid arthritis on the burden of disease in urban China. J Med Econ 2011;14:709-19.
19. MCBRIDE S, SARSOUR K, WHITE LA, NELSON DR, CHAWLA AJ, JOHNSTON JA: Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis. J Rheumatol 2011;38:2141-9.
20. MARAVIC M, BAUDENS G, SANCHEZ JP, FLIPO RM, TOUBIANA L, LANDAIS P: Biotherapy and rheumatoid arthritis: a medicoeconomic evaluation from 2008 French Hospital Database. Joint Bone Spine 2012;79:96-7.
21. METSIOS GS, STAVROPOULOS-KAUNOGLOU A, TREHARNEG J et al.: Disease activity and low physical activity associate with number of hospital admissions and length of hospitalisation in patients with rheumatoid arthritis. Arthritis Res Ther 2011 29;13:R108.
22. FIRTH J, NELSON EA, BRIGGS M, GORECKI C: A qualitative study to explore the impact of foot ulceration on health-related quality of life in patients with rheumatoid arthritis. Int J Nurs Stud 2011;48:1401-8.
23. BOONEN A, SEVERENS JL: The burden of illness of rheumatoid arthritis. Clin Rheumatol 2011;30(Suppl. 1):S3-8.
24. MARRA CA, BANSBACK N, ANIS AH, SHOJANIA K: Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clin Rheumatol 2011;30(Suppl. 1):S9-18.
25. BREEDVELD F: The value of early intervention in RA-a window of opportunity. Clin Rheumatol 2011;30(Suppl. 1):S33-9.
26. ZHU TY, TAM LS, LI EK: Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. Rheumatology (Oxford) 2011;50:1293-301.
27. HALLER TE, HUSBERG M, SKOGH T: 28-Joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project. Rheumatology (Oxford) 2011;50:1259-67.
28. KIRCHHOFF T, RUOF J, MITTENDORF T et al.: Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings. Rheumatology (Oxford) 2011;50:756-61.
29. BERESNIAK A, GOSSEC L, GOUPILLE P et al.: Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol 2011;38:439-45.
30. SCOTT DL, WOLFE F, HUIZINGA TW: Rheumatoid arthritis. Lancet 2010;376:1094-108.
31. MARAVIC M: Economic impact of rheumatoid arthritis (RA) biotherapies in France. Joint Bone Spine 2010;77:319-24.
32. BRACH M, SABARIEGO C, HERSCHBACH P, BERG P, ENGST-HASTREITER U, STUCKI G: Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in chronic arthritis patients. J Public Health (Oxford) 2010;32:547-54.
33. BEARD AJ, SLEATH B, BLALOCK SJ et al.: Predictors of rheumatoid arthritis patientphysician communication about medication costs during visits to rheumatologists. Arthritis Care Res (Hoboken) 2010;62:632-9.
34. FEELY MG, ODELL JR: Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr Opin Rheumatol 2010;22:316-20.
35. FRANKE LC, AMENT AJ, VAN DE LAAR MA, BOONEN A, SEVERENS JL: Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S118-23.
36. BOONEN A, MAU W: The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S112-7.
37. SARAUX A, GOSSEC L, GOUPILLE P et al.: Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 2010;49:733-40.
38. KOBELT G, LINDGREN P, GEBOREK P: Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. Scand J Rheumatol 2009;38:409-18.
39. BIRNBAUM H, PIKE C, KAUFMAN R, MARYNCHENKO M, KIDOLEZI Y, CIFALDI M: Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90.
40. WOLFE F, MICHAUD K: Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:1563-70.
41. TANAKA E, INOUE E, MANNALITHARA A et al.: Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol 2010;20:46-53
42. MALHAN S, AKBULUT LA, BODUR H, TULUNAY CF: Annual costs of rheumatoid arthritis in Turkey. Rheumatol Int 2010;30:637-41.
43. INOTAI A, MESZAROS A: Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. Int J Technol Assess Health Care 2009;25:190-5.
44. FLIPON E, BRAZIER M, CLAVEL G et al.: Is it possible to identify early predictors of the future cost of chronic arthritis? The VErA project. Fundam Clin Pharmacol 2009;23:105-13.
45. JOYCE AT, SMITH P, KHANDKER R, MELIN JM, SINGH A: Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol 2009;36:743-52.
46. SILVERMAN S, DUKES EM, JOHNSTON SS, BRANDENBURG NA, SADOSKY A, HUSE DM: The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin 2009;25:829-40.
47. CURKENDALL S, PATEL V, GLEESON M, CAMPBELL RS, ZAGARI M, DUBOIS R: Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008;59:1519-26.
48. MARCH LM, BARCENILLA AL, CROSS MJ, LAPSLEY HM, PARKER D, BROOKS PM: Costs and outcomes of total hip and knee joint replacement for rheumatoid arthritis. Clin Rheumatol 2008;27:1235-42.
49. KOBELT G, WORONOFF AS, RICHARD B, PEETERS P, SANY J: Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 2008;75:408-15.
50. BANSBACK N, ARA R, KARNON J, ANIS A: Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. Pharmacoeconomics 2008;26:395-408.
51. FAVALLI EG, MARCHESONI A, COLOMBO GL, SINIGAGLIA L: Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008;26:45-51.
52. CHERMONT GC, KOWALSKI SC, CICONELLI RM, FERRAZ MB: Resource utilization and the cost of rheumatoid arthritis in Brazil. Clin Exp Rheumatol 2008;26:24-31.
53. AL MJ, MANIADAKIS N, GRIJSEELS EW, JANSSEN M: Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 2008;11:589-99.
54. MITTENDORF T, DIETZ B, STERZ R, CIFALDI MA, KUPPER H, VON der SCHULENBURG JM: Personal and economic burden of latestage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology (Oxford) 2008;47:188-93.
55. KHANNA R, SMITH MJ: Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis. Clin Ther 2007;29:2456-67.
56. LUNDKVIST J, KASTANG F, KOBELT G, JONSSON B: The burden of rheumatoid arthritis and access to treatment: determinants of access. Eur J Health Econ 2008;8(Suppl. 2):S87-93.
57. JONSSON B, KOBELT G, SMOLEN J: The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008;8(Suppl. 2):S61-86.
58. BERGMAN MJ: Social and economic impact of inflammatory arthritis. Postgrad Med 2006; Spec No: 5-11.
59. JUILLARD-CONDAT B, CONSTANTIN A, CAMBON-THOMSEN A, BOURREL R, TABOULET F: Impact of etanercept on the costs of rheumatoid arthritis (RA): results from a French observational study. Joint Bone Spine 2008;75:25-8.
60. KAVANAUGH A: Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 2007;21:929-42.
61. JACOBSSON LT, LINDROTH Y, MARSAL L, JURAN E, BERGSTROM U, KOBELT G: Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden. Scand J Rheumatol 2007;36:179-83.
62. PENTEK M, KOBELT G, CZIRJÁK L et al.: Costs of rheumatoid arthritis in Hungary. J Rheumatol 2007;34:1437.
63. ACEVES-AVILA FJ, BENITES-GODÍNEZ V, RAMOS-REMUS C: Cost of medication errors in rheumatic patients in Mexico. Clin Rheumatol 2011;30:1421-4.
64. NEOVIUS M, SIMARD JF, KLARESKOG L, ASKLING J; ARTIS STUDY GROUP: Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 2011;70:1407-14.
65. NEOVIUS M, SIMARD JF, ASKLING J; ARTIS STUDY GROUP: How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis 2011;70:1010-5.
66. ZHANG W, ANIS AH: The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol 2011;30(Suppl. 1):S25-32.
67. FILIPOVIC I, WALKER D, FORSTER F, CURRY AS: Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1083-90.
68. STRAND V, KHANNA D: The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010;28(Suppl. 59):S32-40.
69. BOWMAN SJ, ST PIERRE Y, SUTCLIFFE N et al.: Estimating indirect costs in primary Sjogren's syndrome. J Rheumatol 2010;37:1010-5.
70. SOKKA T, KAUTIAINEN H, PINCUS T et al.: QUEST-RA. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUESTRA study. Arthritis Res Ther 2010;12:R42.
71. van den HOUT WB: The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010;69(Suppl. I):i89-91.
72. BIRNBAUM H, PIKE C, KAUFMAN R, CIFALDI M: Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis. J Occup Environ Med 2009;51:1167-76.
73. HOVING JL, BARTELDS GM, SLUITER JK et al.: Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009;38:246-50.
74. ZHANG W, BANSBACK N, GUH D et al.: Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008;35:1729-36.
75. XIE F: The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2008;59:1027-33.
76. DE AZEVEDO AB, FERRAZ MB, CICONELLI RM: Indirect costs of rheumatoid arthritis in Brazil. Value Health 2008;11:869-77.
77. KOBELT G, JÖNSSON B: The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 2008;8(Suppl. 2):95-106.
78. SHANAHAN EM, SMITH MD, ROBERTS-THOMSON L, ESTERMAN A, AHERN MJ: The effect of rheumatoid arthritis on personal income in Australia. Intern Med J 2008;38:575-9.
79. KINGSLEY G, SCOTT IC, SCOTT DL: Quality of life and the outcome of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011;25:585-606.
80. KIRWAN JR, BOONEN A, HARRISON MJ et al.: OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. J Rheumatol 2011;38:1728-34.
81. YACOUB YI, AMINE B, LAATIRIS A, HAJJAJ-HASSOUNI N: Spinsterhood and its impact on disease features in women with rheumatoid arthritis. Health Qual Life Outcomes 2011;9:58.
82. SOLOMON A, CHRISTIAN BF, WOODIWISS AJ, NORTON GR, DESSEIN PH: Burden of depressive symptoms in South African public healthcare patients with established rheumatoid arthritis: a case-control study. Clin Exp Rheumatol 2011;29:506-12.
83. NDOSI M, LEWIS M, HALE C et al.: A randomised, controlled study of outcome and cost effectiveness for RA patients attending nurse-led rheumatology clinics: study protocol of an ongoing nationwide multi-centre study. Int J Nurs Stud 2011, 48:995-1001.
84. CARREÑO A, FERNÁNDEZ I, BADIA X, VARELA C, ROSET M: Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain. Value Health 2011;14:192-200.
85. STANDFIELD L, NORRIS S, HARVEY C et al.: Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A crosssectional, multicenter study. Clin Ther 2010;32:1329-42.
86. WOLFE F, MICHAUD K: The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010;12:R35.
87. KILTZ U, van der HEUDE D: Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S108-11.
88. ARNE M, JANSON C, JANSON S et al.: Physical activity and quality of life in subjects with chronic disease: chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scand J Prim Health Care 2009;27:141-7.
89. SALAFFI F, CAROTTI M, GASPARINI S, INTORCIA M, GRASSI W: The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
90. VAN DEN HOUT WB, GOEKOOP-RUITERMAN YP, ALLAART CF et al.: Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.
91. RUSSELL AS: Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008;26:831-46.
92. HARRISON MJ, DAVIES LM, BANSBACK NJ, INGRAM M, ANIS AH, SYMMONS DP: The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008;35:592-602.
93. SLATKOWSKY-CHRISTENSEN B, MOWINCKEL P, LOGE JH, KVIEN TK: Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis Rheum. 2007;57:1404-9.
94. BERESNIAK A, RUSSELL AS, HARAOUI B, BESSETTE L, BOMBARDIER C, DURU G: Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007;34:2193-200.
95. BANSBACK N, MARRA C, TSUCHIYA A et al.: Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963-71.
96. BOUMANS MJ, VOS K, GERLAG DM, TAK PP: Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab? Ann Rheum Dis 2012;71:472-3.
97. JOBANPUTRA P: A clinician's critique of rheumatoid arthritis health economic models. Rheumatology (Oxford) 2011;50(Suppl. 4):iv48-iv52.
98. KARLSSON JA, NILSSON JÅ, NEOVIUS M et al.: National EQ-5D tariffs and qualityadjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. Ann Rheum Dis 2011;70:2163-6.
99. HLATKY MA: What we can learn from a decision model: comment on "Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management". Arch Intern Med 2011;171:667-8.
100. SUTER LG, FRAENKEL L, BRAITHWAITE RS: Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. Arch Intern Med 2011;171:657-67.
101. SCHIPPER LG, KIEVIT W, DEN BROEDER AA et al.: Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford) 2011;50:1320-30.
102. SIBBITTWL JR, BAND PA, CHAVEZ-CHIANG NR, DELEA SL, NORTON HE, BANKHURST AD: A randomized controlled trial of the cost-effectiveness of ultrasound-guided intraarticular injection of inflammatory arthritis. J Rheumatol 2011;38:252-63.
103. VAN DER VELDE G, PHAM B, MACHADO M et al.: Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2011;63:65-78.
104. BENUCCI M, SAVIOLA G, BAIARDI P, MANFREDI M: Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life. Rheumatol Int 2011;31:1465-9.
105. SCHOELS M, WONG J, SCOTT DL et al.: Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
106. FINCKH A, BANSBACK N, LIANG MH: Costeffectiveness of biologics in early rheumatoid arthritis. Ann Intern Med 2010;152:333-4.
107. CAVALIERE CM, CHUNG KC: A cost-Utility analysis of nonsurgical management, total wrist arthroplasty, and total wrist arthrodesis in rheumatoid arthritis. J Hand Surg Am 2010;35:379-91.
108. HALLINEN TA, SOINI EJ, EKLUND K, PUOLAKKA K: Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77.
109. BENUCCI M, LI GOBBI F, SABADINI L, SAVIOLA G, BAIARDI P, MANFREDI M: The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients. Int J Immunopathol Pharmacol 2009;22:1147-52.
110. LEKANDER I, BORGSTRÖM F, SVARVAR P, UUNG T, CARLI C, VAN VOLLENHOVEN RF: Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care 2010;26:54-61.
111. BAGUST A, BOLAND A, HOCKENHULL J et al.: Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2009;13(Suppl. 2):23-9.
112. BOERS M: Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann Intern Med 2009;151:668-9.
113. FINCKH A, BANSBACK N, MARRA CA et al.: Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009;151:612-21.
114. BESSETTE L, RISEBROUGH N, MITTMANN N, ROUSSY JP, HO J, ZLATEVA G: Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J Med Econ 2009;12:246-58.
115. BARRA L, POPE JE, PAYNE M: Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009;36:1421-8.
116. LINDGREN P, GEBOREK P, KOBELT G: Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009;25:181-9.
117. VIRKKI LM, KONTTINEN YT, PELTOMAA R et al.: Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2008;26:1059-66.
118. BANSBACK N, ARA R, WARD S, ANIS A, CHOI HK: Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-ofinformation analysis. Pharmacoeconomics 2009;27:25-37.
119. CHEN YF, JOBANPUTRA P, BARTON P et al.: Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278, iii.
120. KONNOPKA A, CONRAD K, BAERWALD C, KÖNIG HH: Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis. Ann Rheum Dis 2008;67:1399-405.
121. BRENNAN A, BANSBACK N, NIXON R et al: Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologies Registry. Rheumatology (Oxford) 2007;46:1345-54.
122. BENUCCI M, IANNAZZO S, ZANIOLO O, SABADINI L: Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. Clin Exp Rheumatol 2010;28:722-7.
123. KARACA-MANDIC P, JOYCE GF, GOLDMAN DP, LAOURI M: Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res 2010;45:1227-50.
124. LU CY, WILLIAMS KM, DAY RO: Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Intern Med J 2001;37:601-6.
125. TUOMINEN R, AZBEL M, HEMMILÄ J, MÖT-TÖNEN T: Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by Health Assessment Questionnaire. Rheumatol Int 2011;31:347-52.
126. OZDEMIR S, JOHNSON FR, HAUBER AB: Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ 2009;28:894-901.
127. SCHIFF MH: Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications. Am J Manag Care 2010;16(9 Suppl.):S243-8.
128. STOCKL KM, SHIN JS, LEW HC et al: Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm 2010;16:593-604.
129. SMOLEN JS, LANDEWE R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
130. BELL KJ, IRWIG L, MARCH LM, HAYEN A, MACASKILL P, CRAIG JC: Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. Pharmacoepidemiol Drug Saf 2010;19:99-105.
131. OSTERGAARD M, CONAGHAN PG, O'CONNOR P et al.: Reducing invasiveness, duration, and cost of magnetic resonance imaging in rheumatoid arthritis by omitting intravenous contrast injection - Does it change the assessment of inflammatory and destructive joint changes by the OMERACT RAMRIS? J Rheumatol 2009;36:1806-10.
132. POLINSKI JM, MOHR PE, JOHNSON L: Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Rheum 2009 15;61:745-54.
133. OLDFIELD V, DHILLON S, PLOSKER GL: Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32.
134. BANSBACK N, MARRA CA, FINCKH A, ANIS A: The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:83-92.
135. JOYCE GF, GOLDMAN DP, KARACA-MANDIC P, LAWLESS GD: Impact of specialty drugs on the use of other medical services. Am J Manag Care 2008;14:821-8.
136. KOBELT G: Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl. 3):iii35-9.
137. WESTHOVENS R, BOONEN A, VERBRUGGEN L et al.: Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 2005;24:615-9.
138. LAPSLEY HM, MARCH LM. TRIBE KL, CROSS MJ, COURTENAY BG, BROOKS PM; ARTHRITIS COST AND OUTCOME PROJECT GROUP: Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002;61:818-21.
139. BANSBACK N, HARRISON M, BRAZIER J et al.: Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 2008;59:1018-26.
140. GEUSKENS GA, BURDORF A, HAZES JM: Consequences of rheumatoid arthritis for performance of social roles-a literature review. J Rheumatol 2007;34:1248-60.
141. WOLFE F, ALLAIRE S, MICHAUD K: The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211-7.
142. VERSTAPPEN SM, BIJLSMA JW, VERKLEIJ H et al.: Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
143. DE CROON EM, SLUITER JK, NIJSSEN TF, DIJKMANS BA, LANKHORST GJ, FRINGS-DRESEN MH: Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004;63:1362-7.
144. CHUNG CP, SOKKA T, ARBOGAST PG, PINCUS T: Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006;65:1653-7.
145. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
146. WELLS GA, TUGWELL P, KRAAG GR, BAKER PR, GROH J, REDELMEIER DA: Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
147. KOSINSKI M, ZHAO SZ, DEDHIYA S, OSTERHAUS JT, WARE JE JR.: Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
148. MARRA CA, WOOLCOTT JC, KOPEC JA et al.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
149. SCOTT DL, STRAND V: The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology 2002;41:899-909.
150. SCOTT DL, SMITH C, KINGSLEY G: Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003;21(Suppl. 31):S20-7.
151. MARGARETTEN M, YELIN E, IMBODEN J et al.: Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. Arthritis Rheumatism 2009;61:1586-91.
152. MARGARETTEN M, BARTON J, JULIAN L et al: Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res 2011;63:240-6.
153. RADNER H, SMOLEN JS, ALETAHA D: Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology 2011;50:381-8.
154. GULFE A, KRISTENSEN LE, SAXNE T, JACOBSSON LT, PETERSSON IF, GEBOREK P: Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care Res 2010;62:1399-406.
155. HARRISON MJ, TRICKER KJ, DAVIES L et al.: The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol 2005;32:2330-6.
156. WOLFE F, MICHAUD K, LI T, KATZ RS: Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010;37:305-15.
157. SYMMONS D, TRICKER K, ROBERTS C, DAVIES L, DAWES P, SCOTT DL: The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005;9:1-78.
158. CIMMINO M, LEARDINI G, SALAFFI F et al.: Assessing the cost-effectiveness of biologic agents for the management of moderateto-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol 2011;29:633-41.
159. CONTRERAS-YÁÑEZ I, RULL-GABAYET M, PASCUAL-RAMOS V: Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Clin Exp Rheumatol 2012;30:402-8.
160. MOSCA M, TANI C, ARINGER M, et al.: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011;10:383-8.
161. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
162. TURCHETTI, G, SPADONI E, GEISLER E: Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Engineering in Medicine and Biology Magazine 2010;29:70-6.
163. TURCHETTI G, SCALONE L, DELLA CASA ALBERIGHI O et al.: The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 2012;30(Suppl.73):S64-S71.
164. PALLA I, TRIESTE L, TANI C et al.: A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 2012;30(Suppl. 73):S136-S141.
165. TURCHETTI G, YAZDANY J, PALLA I, YELIN E, MOSCA M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012;30(Suppl. 73):S116-S122.
166. MOSCA M, BOUMPAS D, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012;30(Suppl. 73):S112-S115.
167. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S154-S156.
168. TRIESTE L, PALLA I, FUSCO F et al.: The economic impact of gout: systematic literature review. Clin Exp Rheumatol 2012;30(Suppl. 73):S145-S148.
169. CORTESI PA, SCALONE L, D'ANGIOLELLA L et al.: Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012;30(Suppl. 73):S126-S131.